Subcutaneous Panniculitis-Like T-Cell Lymphoma
A rare type of cutaneous T-cell lymphoma that involves the fatty layer beneath the skin, often presenting as nodules or plaques on the limbs or trunk.
- Rare alpha-beta T-cell lymphoma
- Generally indolent course
- Watch for HLH features
- Skin-directed and systemic options
- Most Common In
- Adults & adolescents
- Typical Presentation
- Subcutaneous nodules/plaques
- Disease Course
- Usually indolent (alpha-beta type)
- Key Risk
- Hemophagocytic syndrome (HLH)
- Advanced Therapies
- Available for refractory disease
Condition Overview
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare lymphoma that arises from cytotoxic T-cells and infiltrates the subcutaneous fat, mimicking inflammatory panniculitis on both clinical exam and early biopsy. Most cases express an alpha-beta T-cell receptor and follow an indolent course, with a smaller subset showing aggressive behavior, particularly when associated with hemophagocytic lymphohistiocytosis (HLH).
Types and Subtypes
SPTCL is classified primarily by T-cell receptor expression and the presence or absence of systemic inflammatory complications.
Symptoms and Signs
SPTCL typically presents with skin findings that can be mistaken for benign panniculitis, so persistent or recurrent nodules warrant biopsy.
Causes and Risk Factors
The exact cause of SPTCL is not well understood, and no strong environmental or lifestyle trigger has been established.
Diagnosis and Investigations
Diagnosis requires deep skin biopsy with specialized immunohistochemistry and molecular testing, since SPTCL closely resembles benign panniculitis on routine pathology.
Staging and Risk Groups
SPTCL does not use a dedicated TNM staging system; risk stratification instead centers on disease extent and presence of hemophagocytic syndrome.
Standard Treatment
Treatment is tailored to disease extent and the presence of hemophagocytic syndrome, ranging from skin-directed therapy to systemic immunosuppression or chemotherapy.
Advanced & Emerging Therapies
For relapsed or refractory SPTCL, novel agents and cellular therapies used in other T-cell lymphomas are being explored.
Targeted Immunotherapy
Histone deacetylase (HDAC) inhibitors
Used in some relapsed/refractory peripheral T-cell lymphomas; considered case-by-case.
Cellular Therapy
CAR-T and cellular immunotherapy research
Investigational approaches being studied in T-cell lymphomas, with selective access through trials.
International Access
China-based clinical trial coordination
CancerFax can help connect patients with refractory disease to international trial opportunities.
Biomarkers & Precision Medicine
Immunophenotyping and molecular markers help confirm diagnosis and distinguish SPTCL from more aggressive lookalike lymphomas.
When to Seek a 2nd Opinion
Because SPTCL is rare and can mimic benign skin conditions, a second specialist opinion is often valuable, especially around diagnosis and treatment intensity.
Clinical Trials & Research
Prognosis & Outcomes
Outcomes for alpha-beta SPTCL without hemophagocytic syndrome are generally favorable, while disease complicated by HLH carries a more guarded course.
Supportive Care
Supportive care focuses on skin wound management, infection prevention during immunosuppression, and monitoring for hemophagocytic complications.
How CancerFax Helps You Explore Treatment Options
CancerFax can help you get expert review of your pathology and connect you with specialists experienced in rare T-cell lymphomas like SPTCL.
Get a free case reviewFrequently Asked Questions
SPTCL is a rare lymphoma where malignant T-cells infiltrate the fatty layer beneath the skin, often appearing as firm nodules that can mimic benign panniculitis.
The most common early sign is one or more firm, subcutaneous nodules or plaques, often on the arms or legs, sometimes with mild fever or fatigue.
No. Panniculitis is inflammation of subcutaneous fat with many possible causes, while SPTCL is a malignant lymphoma that can closely resemble it on initial biopsy.
Diagnosis requires a deep skin biopsy with specialized immunohistochemistry and molecular testing to confirm clonal T-cell infiltration and phenotype.
HLH is a serious immune activation syndrome that can occur alongside SPTCL, causing fevers, cytopenias, and organ dysfunction; it requires urgent treatment.
Many patients with alpha-beta SPTCL without hemophagocytic syndrome achieve durable disease control with treatment, though outcomes vary by individual case.
Treatment ranges from systemic corticosteroids and immunosuppressants for limited disease to chemotherapy for more extensive or complicated cases.
Recurrence is possible, which is why ongoing skin monitoring and periodic follow-up are recommended even after a good initial response.
Given how rare this lymphoma is, a second specialist opinion on pathology and treatment planning can help confirm the diagnosis and refine your care plan.
Yes. CancerFax can help you organize and submit your medical reports for specialist review, request a second opinion, explore advanced or investigational therapy options, and coordinate access to international centers, including in China, if appropriate for your case.
Get Expert Guidance on Your SPTCL Diagnosis
Send your pathology and imaging reports to CancerFax for review and explore treatment options with specialist support.